Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793197 | 0.90 | ATR (0.42) | ATRCA12CA1CA9CA2 | |
| SCHEMBL2960138 | 0.87 | CA12 (0.41) | ATRCA12CA1CA9CA2 | |
| SCHEMBL17185574 | 0.85 | ATR (0.39) | ATRCA12CA1CA9CA2 | |
| SCHEMBL8571236 | 0.83 | CA12 (0.43) | ATRCA12CA1CA9CA2 | |
| SCHEMBL8569699 | 0.83 | TAS1R3 (0.46) | ATRCA12CA1CA9KDM4E | |
| SCHEMBL24449312 | 0.82 | CA12 (0.45) | ATRCA12CA1CA9CA2 | |
| SCHEMBL282268 | 0.82 | DHODH (0.45) | ATRCA12CA1CA9CA2 | |
| SCHEMBL16137967 | 0.81 | MAPT (0.41) | ATRCA12CA1CA9KDM4E | |
| SCHEMBL4213410 | 0.81 | MAPKAPK2 (0.43) | ATRCA12CA1CA9CA2 | |
| SCHEMBL12527218 | 0.79 | MAPT (0.58) | ATRKDM4EALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-05-20 | — | — | US | disclosed |
| EP-3229801-B1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME (US) | 2020-04-01 | — | — | EP | disclosed |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-10189819-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME, CORP. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180030036-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-3229801-A1 | FACTOR IXA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094260-A1 | FACTOR IXA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | SARCODE BIOSCIENCE INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9248126-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9216174-B2 | Modulators of cellular adhesion | SARCODE BIOSCIENCE INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745460-B2 | Modulators of cellular adhesion | SARCODE CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | BAUSCH + LOMB IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176896-A1 | Modulators of cellular adhesion | BAUSCH + LOMB IRELAND LIMITED (IE) | 2008-07-24 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314938-B2 | Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145824-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ATR 3603/4885CA12 4549/4885CA1 4605/4885 |
| US-20080176896-A1 | Modulators of cellular adhesion | ITGB1, VCAM1, ITGB8 | ATR 3603/4885CA12 4549/4885CA1 4605/4885 |
| US-20100093693-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ATR 3616/4885CA12 4551/4885CA1 4618/4885 |
| US-20160074381-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ATR 3603/4885CA12 4549/4885CA1 4605/4885 |
| US-20180030036-A1 | Factor IXa Inhibitors | F9, TFPI, F12 | ATR 4388/4885CA12 1524/4885CA1 799/4885 |
| US-20190134022-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ATR 3603/4885CA12 4549/4885CA1 4605/4885 |
| US-20080182839-A1 | MODULATORS OF CELLULAR ADHESION | ITGB1, VCAM1, ITGB8 | ATR 3604/4885CA12 4549/4885CA1 4600/4885 |
| US-10189819-B2 | Factor IXa inhibitors | F9, TFPI, F12 | ATR 4388/4885CA12 1524/4885CA1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.